GlaxoSmithKline's immunology leader Nucala has been locked in a yearslong struggle with AstraZeneca's Fasenra for dominance in rare eosinophilic asthma. With a new rare disease approval, Nucala just ...
Yesterday, GSK added a new antibody-drug conjugate to its cancer pipeline via a $358 million agreement with French biotech ...
GlaxoSmithKline’s Nucala needs a win in its fight against AstraZeneca’s Fasenra. Now, it can at least tout a first-data advantage in a rare inflammatory disease. In a phase 3 study, the rate of ...
Third US indication for Nucala demonstrates GSK’s commitment to finding new ways to help patients with eosinophil-driven diseases Dr Hal Barron, Chief Scientific Officer and President R&D, GSK, said: ...
Pharmaceutical Technology on MSN
GSK forges pact with Empirico for respiratory siRNA in $745m deal
GSK now has the global development and commercialisation rights to the COPD-targeting oligonucleotide, EMP-012.
Previously, the treatment had only been available as a lyophilized powder for reconstitution that required administration by a healthcare professional. The Food and Drug Administration has approved ...
GSK is shelling out $85 million up front, and possibly $745 million overall, for an RNA-based therapy it sees helping a ...
(Reuters) -British drugmaker GSK said on Friday that its asthma drug, Nucala, met the main goal of a late-stage study in treating patients with chronic obstructive pulmonary disease (COPD), or ...
The approval was based on data from the phase 3 SYNAPSE study that evaluated mepolizumab as an add-on maintenance treatment in over 400 adults with CRSwNP. The Food and Drug Administration (FDA) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback